Ascendis Pharma A/S

NASDAQ:ASND

Biotechnology

Healthcare
$270.33 -0.02%

-$0.05 today

Market cap
$17.73B
Beta
0.39
P/E (TTM)
24.5
EPS (TTM)
$8.21
52W Low $160.86High $250.74

Volume 0.57M

Average 0.64M

ASND Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Ascendis Pharma A/SNASDAQ: ASND

Operating Income · Q3 FY2026 · quarter ended Sep 2026

Operating income growth accelerates

Q3 FY2026 operating income of €123.84M rose 1026.1% year over year, ahead of the +252.5% change in trailing-twelve-month operating income. Sequentially, it rose 95.2% from the prior quarter.

Context

  • Operating income amounted to 18.9% of revenue in FY2025, down 57.7 pp from a year earlier.
  • Operating income grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 13 analysts of €1.23B (+1036.5%) for the fiscal year ending Dec 2026, a step up from the +53.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
€123.84M+95.2% QoQ
Last fiscal yearDec 2025
-€130.89M+53.0% YoY
LTMSep 2026
€222.29M+252.5% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1026.1%-3482.9%-4509.0 pp
1 year+53.0%+1036.5%+983.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

EUR · from the income statement

Latest · FY2025
(130.89M) EUR
Year-over-year change
+53.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How ASND compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +252.5% is the 2nd highest of 11, against a peer median of -6.2%.
  • Operating income amounts to 18.4% of revenue for ASND, versus a peer median of 44.5%.
ASND Competitors
Operating Income for ASND and competitors
Company Period LTM YoY 3-year CAGR% of revenue
UTHRUnited Therapeutics CorporationLTM Jun 2026$1.4B USD-3.1%+15.7%44.5%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$881.2M USD+60.2%+35.5%23.8%
ASNDAscendis Pharma A/SLTM Sep 2026€222.29M EUR+252.5%—18.4%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$35.9M USD+259.6%—11.4%
CORTCorcept Therapeutics IncorporatedLTM Jun 2026$6.41M USD-93.7%-26.5%0.8%
SEPNSepterna, Inc.LTM Sep 2026-$73.39M USD+4.7%—76.2%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026-$160.33M USD-76.4%——
STOKStoke Therapeutics, Inc.LTM Mar 2026-$185.25M USD-584.4%—577.5%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-$561.78M USD-9.4%—83.9%
INSMInsmed IncorporatedLTM Jun 2026-$817.54M USD+18.6%—71.9%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-$81.76B USD-13383.8%+49.1%8.0%
Peer median (excluding ASND) —-6.2%+25.6%44.5%

Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.78M51.17M266.72M363.64M691.71M
Cost of Revenue3.52M12.14M44.4M44.26M103.18M
Gross Profit4.26M39.04M222.32M319.38M588.53M
Gross Margin54.7%76.3%83.4%87.8%85.1%
Research & Development295.87M379.62M413.45M307M283.5M
Selling, General & Admin160.18M215.85M258.79M284.55M435.92M
Operating Expenses456.05M600.85M677.86M598.15M719.42M
Depreciation & Amortization15.39M17.96M18.91M17.71M17M
EBITDA(364.64M)(529.18M)(411.17M)(290.02M)(109.8M)
EBITDA Margin-4688.1%-1034.1%-154.2%-79.8%-15.9%
Operating Income(451.79M)(561.81M)(455.54M)(278.76M)(130.89M)
Operating Margin-5808.6%-1097.9%-170.8%-76.7%-18.9%
Interest Income692K7.43M16.86M14.36M14.7M
Interest Expense3.91M30.68M44.07M65.5M77.46M
Other Income / Expenses67.85M(16M)(18.6M)(94.48M)(73.37M)
Income Before Tax(383.94M)(577.82M)(474.14M)(373.24M)(204.26M)
Pre-Tax Margin-4936.3%-1129.1%-177.8%-102.6%-29.5%
Income Tax Expense(367K)5.38M7.3M4.84M14.78M
Net Income(383.58M)(583.19M)(481.45M)(378.08M)(219.03M)
Net Margin-4931.6%-1139.6%-180.5%-104.0%-31.7%
EPS (Basic)(7.00)(10.40)(8.55)(6.53)(3.62)
EPS (Diluted)(7.00)(10.40)(8.55)(6.53)(3.62)
Weighted Avg Shares54.77M56.07M56.29M57.89M60.61M
Weighted Avg Shares (Diluted)54.77M56.07M56.29M57.89M60.61M

Ascendis Pharma A/S

NASDAQ:ASND

Intrinsic Alpha fair value

Locked

Current Price

$270.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.